CN109207536B - Method for increasing content of milbemycin A3 in milbemycin fermentation product - Google Patents

Method for increasing content of milbemycin A3 in milbemycin fermentation product Download PDF

Info

Publication number
CN109207536B
CN109207536B CN201711295635.9A CN201711295635A CN109207536B CN 109207536 B CN109207536 B CN 109207536B CN 201711295635 A CN201711295635 A CN 201711295635A CN 109207536 B CN109207536 B CN 109207536B
Authority
CN
China
Prior art keywords
fermentation
percent
acetate
culture
liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201711295635.9A
Other languages
Chinese (zh)
Other versions
CN109207536A (en
Inventor
赵子刚
张葵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHONGQING DAXIN PHARMACEUTICAL CO LTD
New Founder Holdings Development Co ltd
Peking University Medical Management Co ltd
Original Assignee
CHONGQING DAXIN PHARMACEUTICAL CO LTD
Peking University Founder Group Co Ltd
PKU Healthcare Industry Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHONGQING DAXIN PHARMACEUTICAL CO LTD, Peking University Founder Group Co Ltd, PKU Healthcare Industry Group filed Critical CHONGQING DAXIN PHARMACEUTICAL CO LTD
Priority to CN201711295635.9A priority Critical patent/CN109207536B/en
Publication of CN109207536A publication Critical patent/CN109207536A/en
Application granted granted Critical
Publication of CN109207536B publication Critical patent/CN109207536B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention discloses a method for increasing the content of milbemycin A3 in a milbemycin fermentation product, which comprises the following steps: the method comprises the steps of slant strain culture, liquid seed culture, liquid fermentation culture and the like, wherein a supplemented sucrose solution is fed into fermentation liquor in the fermentation culture process, particularly after fermentation is carried out for 48 hours, a sodium acetate solution with the specificity of 0.05 percent of precursor is intermittently or continuously supplemented into the fermentation liquor every day, so that the content of A3 in a fermentation product is obviously improved, and the fermentation yield of the milbemycins is also improved.

Description

Method for increasing content of milbemycin A3 in milbemycin fermentation product
Technical Field
The invention relates to a fermentation process of milbemycins, belongs to the technical field of biological pharmacy, and particularly relates to a method for producing milbemycins by using a microbial liquid submerged fermentation technology.
Background
Milbemycins (milbemycins) are mixtures of a series of sixteen-membered macrolide antibiotics produced by fermentation of Streptomyces hygroscopicus (Streptomyces hygroscopicus). Most of more than 20 components of the milbemycins have broad-spectrum control activity on agricultural pests, such as aphids, mites, tentacles fulvidraco, intestinal parasites and other parasites which harm crops and livestock, and particularly have higher control effect on various mites. The milbemycins have the characteristics of strong action on pests, small dosage, safety to people and livestock, no environmental pollution, only killing the pests, no killing of natural enemies of the pests and no easy generation of drug resistance, and are a promising broad-spectrum, high-efficiency, novel and non-cross-resistance biological pesticide.
In the milbemycins, because the milbemycins A3 and A4 have strong biological activity and high yield, the commercialization of the milbemycins is performed around the milbemycins A3 and A4. Besides the wide use of the mixture of milbemycins A3, A4 as acaricides, the semisynthetic oximation products of milbemycins A3, A4, and Milbemycin oxime (Milbemycin oxime, CAS number: 129496-10-2), which is a novel macrocyclic lactone anthelmintic, has good effect on killing endoparasites and ectoparasites, and has good effect on controlling and preventing most common pet parasitic diseases. The milbemycin oxime is recognized as a broad-spectrum, efficient and safe anthelmintic especially due to the characteristics of low toxicity and high efficiency, and is especially safe for some dogs sensitive to ivermectin.
The milbemycin oxime is formed by mixing milbemycin oxime A3 and milbemycin oxime A4 according to a certain proportion, and the content of the milbemycin oxime A3+ A4 is required to be not less than 95%, wherein the proportion of A3 and A4 is (20 +/-5): (80. + -.5). The structural formulas of the milbemycin oxime A3 and A4 are shown as the following formulas:
Figure BDA0001500261270000021
milbemycin Oxime A3(Milbemycin Oxime A3): r is CH3
Milbemycin Oxime a4(Milbemycin Oxime a 4): r is CH2CH3
In the industrial production of milbemycins, Streptomyces hygroscopicus (Streptomyces hygroscopicus) is mainly used for fermentation production, and in the fermentation process, milbemycins A3 and A4 are produced by thalli simultaneously and exist in a fermentation liquid in the form of a mixture. Because the structures and properties of A3 and A4 are very similar, only the substituents on C-25 are different and are methyl and ethyl respectively, and the separation of single components of A3 and A4 from fermentation liquor is very difficult, at present, the A3 and A4 are generally regarded as the same component in industry, and are extracted and separated from the fermentation liquor together, and then subjected to a series of semi-synthesis steps such as oxidation, oximation and the like, and finally separated and purified to obtain the finished product of the milbemycin oxime. This requires that the ratio of milbemycins A3 to A4 in the fermentation broth must be exactly (20. + -.5): (80 +/-5) so that the ratio of the finally obtained milbemycin oxime A3 to A4 can meet the requirement.
At present, a problem is encountered in domestic milbemycin oxime fermentation production, the total fermentation unit of milbemycin continuously increases with the continuous fermentation process of each batch of fermentation, but the fermentation unit of A3 in the middle and later stages of fermentation relatively slowly increases, so that the proportion of A3/A4 also continuously decreases from about 1:3 in the middle stage of fermentation to about 1:7 before tank placement, and the requirement of a final product is about 1:4, so the milbemycin oxime is often placed in the tank in advance when the fermentation unit is still low. The difficulty in production needs to find a method which can specifically improve the yield of A3 without affecting the yield of A4, so that the yield of milbemycin can be improved on the whole, the difficulty in the subsequent semi-synthesis production of milbemycin can be greatly reduced, and the production cost is greatly reduced.
According to the analysis of 400MHz 13C nuclear magnetic resonance spectrum of the alpha 2, alpha 4 and D components of the milbemycins, the carbon on the glycoside skeleton is derived from 7 acetate and 5 propionate, and the structure of the glycoside skeleton is completely the same as that of the abamectin. Therefore, it was concluded from the avermectin synthetic pathway (H Ikeda, S Omura. control of avermectin biosynthesis in Streptomyces avermitilis for the selective production of a usesul component, Chemiform, 1996,27(1):549-62) that the methyl substituent at C-25 of the milbemycin A3 component was derived from acetate metabolism and the ethyl substituent at C-25 of the A4 component was derived from propionate metabolism.
Disclosure of Invention
On the basis of the existing technology for producing the milbemycins by fermentation, the invention solves the technical problem of slow increase of the output of the milbemycins A3 in the middle and later stages of the fermentation by adding a proper amount of specific precursor sodium acetate in the fermentation process, and provides a process method capable of specifically increasing the fermentation output of the milbemycins A3, thereby improving the proportion of A3 in the milbemycins fermentation products.
The inventor finds that the milbemycins are secondary metabolites of streptomyces hygroscopicus, the specific ligands in the structure of the milbemycins A3 are derived from acetate, and the specific ligands in the structure of the milbemycins A4 are derived from propionate, so that the acetate is a specific precursor substance for the biosynthesis of the milbemycins A3, and the addition of acetate in the fermentation broth can increase the synthesis of the milbemycins A3 without affecting the synthesis of A4, so that the yield of A3 can be increased by a method of adding a proper amount of sodium acetate in the fermentation broth, and the yield of A4 is not increased, and the aim of improving the proportion of A3/A4 is fulfilled. The inventor proves through experiments that the yield of the milbemycin A3 can be improved in a small degree by adding a proper amount of sodium acetate in a fermentation formula, and meanwhile, the yield of the milbemycin A4 is not influenced basically.
On the basis of the research, the addition of a proper amount of acetate in the fermentation medium of the milbemycins is presumed to save the time and nutrition required by the bacteria for synthesizing acetate by themselves, so that the yield of A3 is improved, but experiments show that the effect of improving the yield of A3 is not obvious by adopting a measure of adding acetate in the fermentation basic medium, after the fermentation period is 48 hours, the primary metabolism is basically completed, and the acetate is supplemented when the secondary metabolism occupies the main position, so that the effect is better, and particularly, the effect of supplementing each time every day or continuously feeding is better.
On the basis of the research, the fermentation yield and the fermentation proportion of the milbemycin A3 are remarkably improved by the following technical means:
(1) slant culture of strain: inoculating Streptomyces hygroscopicus strain to slant culture medium, and culturing at 27-29 deg.C and 20-60% humidity for 10-12 days to obtain mature slant strain. The formula of the slant culture medium comprises 0.4% of sucrose, 0.1% of skimmed milk powder, 0.2% of yeast powder, 0.1% of peptone and 2.0% of agar.
(2) Liquid seed culture: scraping a proper amount of spores from mature slant strains, inoculating the spores into a liquid seed culture medium, and culturing for 40-48 hours at the temperature of 27-29 ℃ and the stirring speed of 100-. The formula of the liquid seed culture medium comprises 2 percent of sucrose, 0.1 percent of skim milk powder, 0.5 percent of soybean cake powder, 0.5 percent of peptone and 0.1 percent of calcium carbonate.
(3) Liquid fermentation culture: inoculating mature seed liquid into a fermentation culture medium according to the inoculation amount of 4-12%, fermenting and culturing at the temperature of 27-29 ℃ under the conditions of stirring speed of 100-. The fermentation is finished after 240-288h fermentation, and the fermentation broth containing the milbemycin is obtained. The formula of the liquid fermentation medium is as follows: 8 percent of cane sugar, 1.0 percent of skim milk powder, 1.0 percent of soybean cake powder, 1.0 percent of peptone, 0.5 percent of dipotassium hydrogen phosphate, 0.1 percent of ferrous sulfate, 0.01 percent of zinc sulfate, 0.05 percent of copper sulfate, 0.05 percent of sodium molybdate and 0.5 percent of calcium carbonate.
(4) Fermentation precursor supplement: after fermentation for 48 hours, 0.05 percent of sodium acetate is supplemented into the fermentation liquor every day, the sodium acetate is prepared into a solution with the concentration of 5 percent, and after sterilization, the sodium acetate solution is supplemented into a fermentation tank every day according to 1 percent of the volume of the fermentation liquor.
The technical scheme of the invention is as follows:
a method for increasing the content of milbemycin A3 in milbemycin fermentation product comprises adding a certain amount of acetate into the fermentation liquid during fermentation.
Further, the acetate comprises one or more of sodium acetate, potassium acetate, ammonium acetate, zinc acetate and the like, and is preferably sodium acetate.
Further, the acetate is added in the form of a solution; the concentration of the acetate solution used is generally 0.5% to 20% (mass fraction); preferably a 5% strength sodium acetate solution.
Further, at 48h of fermentation, the fermentation broth is supplemented daily with a certain amount of acetate (preferably sodium acetate) solution until the end of the fermentation.
Further, the amount of acetate to be fed to the fermentation broth per day is 0.01 to 0.1% (referring to the mass fraction of the fed acetate in the fermentation broth), preferably 0.05%.
Further, the acetate is supplemented to the fermentation broth in an intermittent manner once a day or in a continuous fed-batch manner.
Further, when the total sugar concentration in the fermentation broth is reduced to below 2.0% (mass fraction, the same applies hereinafter), the sucrose solution is added to maintain the total sugar concentration in the fermentation broth between 1.5 and 2.5%.
Further, after fermenting for 150h to 120-.
Further, sucrose supplementation is stopped 12h before the tank is placed (fermentation is finished).
Further, fermentation was terminated after 240-288h fermentation.
Further, the fermentation conditions include: the temperature is 27-29 ℃, the stirring speed is 100-.
In general, fermentation can be carried out using microorganisms that produce milbemycins as are conventional in the art, such as Streptomyces hygroscopicus (Streptomyces hygroscopicus).
On the basis of the common knowledge in the field, the above preferred conditions can be combined with each other to obtain the preferred embodiments of the invention.
Specifically, the method for increasing the proportion of the milbemycin A3 in the milbemycin fermentation product comprises the following steps:
1) slant culture of bacterial
Inoculating Streptomyces hygroscopicus (Streptomyces hygroscopicus) strain to a slant culture medium, and culturing at 27-29 deg.C and 20-60% humidity for 10-12 days to obtain mature slant strain;
the formula of the slant culture medium is as follows: 0.4 percent of sucrose, 0.1 percent of skim milk powder, 0.2 percent of yeast powder, 0.1 percent of peptone and 2.0 percent of agar.
2) Liquid seed culture
Scraping a proper amount of spores from a mature slant strain, inoculating the spores into a liquid seed culture medium, and performing aeration culture for 40-48 hours under the conditions of the temperature of 27-29 ℃, the stirring speed of 100-;
or further carrying out amplification culture on the mature seed liquid again according to the same method;
the formula of the liquid seed culture medium is as follows: 2% of cane sugar, 0.1% of skim milk powder, 0.5% of soybean cake powder, 0.5% of peptone and 0.1% of calcium carbonate;
typically, the seed liquid is inoculated in an amount of 1% to 8%.
3) Liquid fermentation culture
Inoculating mature seed liquid into a fermentation culture medium according to the inoculation amount of 4-12%, and performing aeration fermentation culture at the temperature of 27-29 ℃ and the stirring rotation speed of 100-;
the formula of the liquid fermentation medium is as follows: 8 percent of cane sugar, 1.0 percent of skim milk powder, 1.0 percent of soybean cake powder, 1.0 percent of peptone, 0.5 percent of dipotassium hydrogen phosphate, 0.1 percent of ferrous sulfate, 0.01 percent of zinc sulfate, 0.05 percent of copper sulfate, 0.05 percent of sodium molybdate and 0.5 percent of calcium carbonate;
4) when the fermentation time is 48 hours, sodium acetate solution with the concentration of 5 percent is supplemented into the fermentation liquor every day, the amount of the sodium acetate supplemented into the fermentation liquor every day is 0.01-0.1 percent (referring to the mass fraction of the supplemented sodium acetate in the fermentation liquor), and the preferred amount is 0.05 percent until the end of the fermentation;
the sodium acetate solution is supplemented intermittently once a day or continuously fed;
5) sampling and detecting the total sugar concentration in the fermentation liquid after fermenting for 150h after 120-f, and when the total sugar concentration is reduced to be below 2.0%, starting to supplement the sucrose solution, maintaining the total sugar concentration in the fermentation liquid to be between 1.5 and 2.5%, stopping supplementing sugar 12h before the fermentation is placed in a tank, and ending the fermentation after fermenting for 288 h.
The invention also comprises a fermentation product prepared by the method.
The invention has the beneficial effects that:
the invention provides a method for specifically improving the fermentation yield of milbemycin A3, and basically has no influence on the yield of milbemycin A4, so that the proportion of a milbemycin A3 component in a final product is improved. The process method solves the problem that the fermentation yield of the milbemycins A3 in the middle and later stages of the traditional milbemycins fermentation is slowly increased, so that the milbemycins A3 and A4 can be synchronously increased, the proportion of the milbemycins A3 in the fermentation product in the later stage of the fermentation is improved, the fermentation period is prolonged, and the fermentation yield of the milbemycins is obviously improved.
Detailed Description
The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention. The examples do not show the specific techniques or conditions, according to the technical or conditions described in the literature in the field, or according to the product specifications. The reagents or instruments used are conventional products available from regular distributors, not indicated by the manufacturer.
Slant culture was used as follows: inoculating Streptomyces hygroscopicus strain to slant culture medium, and culturing at 27-29 deg.C and 20-60% humidity for 10-12 days to obtain mature slant strain. The formula of the slant culture medium is as follows: 0.4 percent of sucrose, 0.1 percent of skim milk powder, 0.2 percent of yeast powder, 0.1 percent of peptone and 2.0 percent of agar.
The following formula of the liquid seed culture medium is as follows: 2 percent of cane sugar, 0.1 percent of skim milk powder, 0.5 percent of soybean cake powder, 0.5 percent of peptone and 0.1 percent of calcium carbonate.
The following formula of the liquid fermentation medium is as follows: 8 percent of cane sugar, 1.0 percent of skim milk powder, 1.0 percent of soybean cake powder, 1.0 percent of peptone, 0.5 percent of dipotassium hydrogen phosphate, 0.1 percent of ferrous sulfate, 0.01 percent of zinc sulfate, 0.05 percent of copper sulfate, 0.05 percent of sodium molybdate and 0.5 percent of calcium carbonate.
Example 1
(1) Taking the slant of the grown strain, scraping spores on the slant of about 0.5cm multiplied by 0.5cm, inoculating the spores into a 500ml seed shake flask with the capacity of 50ml, and culturing the inoculated seed shake flask on a shaking table with the rotating speed of 180rpm at 28 ℃ for 48 h.
(2) Inoculating the cultured shake flask seeds to a 5L glass fermentation tank according to the inoculation amount of 8%, wherein the loading amount of the fermentation tank is 2.5L, the culture condition of the fermentation tank is that the tank temperature is 28 ℃, the ventilation volume is 0.8vvm, the stirring speed is 200rpm, and the Dissolved Oxygen (DO) value on the fermentation tank is controlled to be more than or equal to 30% by increasing the stirring speed in the fermentation process.
(3) When the fermentation culture is carried out for 48 hours, the sterilized sodium acetate solution with the concentration of 5% is supplemented once a day, 25ml is supplemented each time, namely, the sodium acetate is supplemented once when the fermentation is carried out for 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, 192 hours and 216 hours.
(4) When the fermentation culture is carried out for 150 hours, the sucrose supplement solution is fed in, the sucrose concentration in the fermentation liquor is controlled to be 1.5-2.5% by adjusting the sugar supplement speed, and the sugar supplement is stopped when the time is 228 hours.
(5) And (3) finishing the culture when the fermentation culture lasts for 240 hours, taking the fermentation liquor for detection, wherein the content of the total milbemycins in the fermentation liquor is 1.88g/L, the content of the milbemycins A3 is 0.37g/L, and the content of A3: a4 ═ 1: 4.08.
and taking the fermentation liquor of the same batch without being supplemented with sodium acetate as a reference, wherein the content of the total milbemycins in the fermentation liquor is 1.79g/L when the fermentation liquor is cultured for 240h, the content of the milbemycins A3 is 0.25g/L, A3: a4 ═ 1: 6.16.
the fermentation process for supplementing sodium acetate in the batch can improve the yield of the milbemycin A3 by about 48 percent, and the ratio of A3 to A4 is from 1: about 6, improvement by 1: and 4, the requirement of the final product of the milbemycin oxime is met, and the production cost of the milbemycin oxime is greatly reduced.
Example 2
(1) Taking the slant of the grown strain, scraping spores on the slant of about 0.5cm multiplied by 0.5cm, inoculating the spores into a 500ml seed shake flask with the capacity of 50ml, and culturing the inoculated seed shake flask on a shaking table with the rotating speed of 180rpm at 28 ℃ for 48 h.
(2) Inoculating the cultured shake flask seeds to a 10L stainless steel seed tank according to the inoculation amount of 1%, wherein the loading amount of the seed tank is 5.0L, the culture condition of the seed tank is that the tank temperature is 28 ℃, the ventilation volume is 1.0vvm, the stirring speed is 100rpm, the Dissolved Oxygen (DO) value on the seed tank is controlled to be more than or equal to 30% by increasing the stirring speed in the culture process, and the culture time of the seed tank is 24 h.
(3) Inoculating the seed liquid of the cultured seeding tank to a 50L fermentation tank according to the inoculation amount of 8%, wherein the loading amount of the fermentation tank is 30L, the culture condition of the fermentation tank is that the tank temperature is 28 ℃, the ventilation volume is 0.8vvm, the stirring rotating speed is 100rpm, and the Dissolved Oxygen (DO) value on the fermentation tank is controlled to be more than or equal to 30% by increasing the stirring rotating speed in the culture process.
(4) When the fermentation culture is carried out for 48 hours, the sterilized sodium acetate solution with the concentration of 5 percent is supplemented, the supplement amount is 300 ml/day by using a constant-speed flow supplement manner, and the sodium acetate supplement is stopped at 288 hours.
(5) When the fermentation culture is carried out for 150 hours, the sucrose supplement solution is fed in, the sucrose concentration in the fermentation liquor is controlled to be 1.5-2.5% by adjusting the sugar supplement speed, and the sugar supplement is stopped when 276 hours.
(6) And (3) ending the culture when the fermentation culture lasts for 288h, taking the fermentation liquor for detection, wherein the content of the milbemycins in the fermentation liquor is 2.17g/L, the content of the milbemycins A3 is 0.42g/L, and the content of the milbemycins A3: a4 ═ 1: 4.17.
and taking the fermentation liquor of the same batch without being supplemented with sodium acetate as a reference, wherein the content of the total milbemycins in the fermentation liquor is 2.03g/L when the fermentation liquor is cultured for 288h, the content of the milbemycins A3 is 0.26g/L, A3: a4 ═ 1: 6.81.
the fermentation process for supplementing sodium acetate in the batch can improve the yield of the milbemycin A3 by about 62 percent, and the ratio of A3 to A4 is from 1: about 7, improvement by 1: about 4, the requirements of the final product of the milbemycin oxime are met, single components of A3 and A4 do not need to be separated, and the production difficulty and the production cost of the milbemycin oxime are greatly reduced.
Although the invention has been described in detail hereinabove with respect to a general description and specific embodiments thereof, it will be apparent to those skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.

Claims (12)

1. A method for increasing the content of milbemycin A3 in a milbemycin fermentation product is characterized in that when the fermentation is carried out for 48 hours, a certain amount of acetate is supplemented into the fermentation liquor every day until the fermentation is finished; the amount of acetate added to the fermentation broth is 0.01-0.1% per day;
when the total sugar concentration in the fermentation liquor is reduced to below 2.0 percent, adding sucrose solution, and maintaining the total sugar concentration in the fermentation liquor between 1.5 and 2.5 percent;
the fermentation strain is Streptomyces hygroscopicus (Streptomyces hygroscopicus).
2. The method of claim 1, wherein the acetate salt comprises one or more of sodium acetate, potassium acetate, ammonium acetate, and zinc acetate.
3. The method of claim 2, wherein the acetate is added as a solution.
4. A process according to claim 3, characterized in that the acetate solution is used in a concentration of 0.5% to 20%.
5. A method according to claim 3, characterized in that the acetate solution used is a 5% strength sodium acetate solution.
6. The method according to any one of claims 1 to 5, wherein the amount of acetate fed to the fermentation broth per day is 0.05%.
7. The process according to any one of claims 1 to 5, wherein the acetate is fed to the fermentation broth in an intermittent manner once a day or in a continuous fed-batch manner.
8. The method according to any one of claims 1 to 5, wherein the total sugar concentration in the fermentation broth is measured after fermentation for 150 hours and the sucrose solution is started to be added when the total sugar concentration in the fermentation broth is reduced to below 2.0%, so as to maintain the total sugar concentration in the fermentation broth between 1.5 and 2.5%.
9. The method of claim 8, wherein sucrose supplementation is stopped 12 hours before fermentation is completed.
10. The method of any one of claims 1 to 5, wherein the fermentation conditions comprise: the temperature is 27-29 ℃, the stirring speed is 100-; and/or ending the fermentation after 240-288h of fermentation.
11. The method of claim 1, comprising the steps of:
1) slant culture of bacterial
Inoculating Streptomyces hygroscopicus (Streptomyces hygroscopicus) strain to a slant culture medium, and culturing at 27-29 deg.C and 20-60% humidity for 10-12 days to obtain mature slant strain;
the formula of the slant culture medium is as follows: 0.4% of cane sugar, 0.1% of skim milk powder, 0.2% of yeast powder, 0.1% of peptone and 2.0% of agar;
2) liquid seed culture
Scraping a proper amount of spores from a mature slant strain, inoculating the spores into a liquid seed culture medium, and performing aeration culture for 40-48 hours under the conditions of the temperature of 27-29 ℃, the stirring speed of 100-; or further carrying out amplification culture on the mature seed liquid again according to the same method;
the formula of the liquid seed culture medium is as follows: 2% of cane sugar, 0.1% of skim milk powder, 0.5% of soybean cake powder, 0.5% of peptone and 0.1% of calcium carbonate;
3) liquid fermentation culture
Inoculating mature seed liquid into a fermentation culture medium according to the inoculation amount of 4-12%, and performing aeration fermentation culture at the temperature of 27-29 ℃ and the stirring rotation speed of 100-600rpm, wherein the aeration rate is 0.4-1.2vvm, and the dissolved oxygen value on a fermentation tank is controlled to be more than or equal to 30%;
the formula of the liquid fermentation medium is as follows: 8 percent of cane sugar, 1.0 percent of skim milk powder, 1.0 percent of soybean cake powder, 1.0 percent of peptone, 0.5 percent of dipotassium hydrogen phosphate, 0.1 percent of ferrous sulfate, 0.01 percent of zinc sulfate, 0.05 percent of copper sulfate, 0.05 percent of sodium molybdate and 0.5 percent of calcium carbonate;
4) when the fermentation is carried out for 48 hours, sodium acetate solution with the concentration of 5 percent is supplemented into the fermentation liquor every day, and the mass fraction of the sodium acetate supplemented into the fermentation liquor every day is 0.05 percent until the fermentation is finished;
the sodium acetate solution is supplemented intermittently once a day or continuously fed;
5) sampling and detecting the total sugar concentration in the fermentation liquid after fermenting for 150h after 120-f, and when the total sugar concentration is reduced to be below 2.0%, starting to supplement the sucrose solution, maintaining the total sugar concentration in the fermentation liquid to be between 1.5 and 2.5%, stopping supplementing sugar 12h before the fermentation is placed in a tank, and ending the fermentation after fermenting for 288 h.
12. A fermentation product produced by the method of any one of claims 1 to 11.
CN201711295635.9A 2017-12-08 2017-12-08 Method for increasing content of milbemycin A3 in milbemycin fermentation product Active CN109207536B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711295635.9A CN109207536B (en) 2017-12-08 2017-12-08 Method for increasing content of milbemycin A3 in milbemycin fermentation product

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711295635.9A CN109207536B (en) 2017-12-08 2017-12-08 Method for increasing content of milbemycin A3 in milbemycin fermentation product

Publications (2)

Publication Number Publication Date
CN109207536A CN109207536A (en) 2019-01-15
CN109207536B true CN109207536B (en) 2021-12-03

Family

ID=64991763

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711295635.9A Active CN109207536B (en) 2017-12-08 2017-12-08 Method for increasing content of milbemycin A3 in milbemycin fermentation product

Country Status (1)

Country Link
CN (1) CN109207536B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112358979B (en) * 2020-10-16 2021-11-02 内蒙古拜克生物有限公司 Method for producing milbemycins through microbial fermentation
CN117568205B (en) * 2023-10-12 2024-08-16 湖北宏中药业股份有限公司 Milbemycin high-yield strain and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102943102A (en) * 2012-11-20 2013-02-27 江西兴鼎科技有限公司 Method for biosynthesizing virginiamycin by streptomycete
CN102952832A (en) * 2011-08-23 2013-03-06 北大方正集团有限公司 Method for producing Nemadectin through fermenting
CN106148216A (en) * 2015-03-27 2016-11-23 浙江海正药业股份有限公司 A kind of streptomycete and the method producing mibemycin A3 thereof
JP6345768B2 (en) * 2013-04-16 2018-06-20 エシコン・エンド−サージェリィ・インコーポレイテッドEthicon Endo−Surgery,Inc. Drive system separation device for surgical instruments

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62155281A (en) * 1985-12-27 1987-07-10 Sankyo Co Ltd Antibiotic milbemycin compound
JP3147321B2 (en) * 1993-06-03 2001-03-19 三共株式会社 New milbemycin compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102952832A (en) * 2011-08-23 2013-03-06 北大方正集团有限公司 Method for producing Nemadectin through fermenting
CN102943102A (en) * 2012-11-20 2013-02-27 江西兴鼎科技有限公司 Method for biosynthesizing virginiamycin by streptomycete
JP6345768B2 (en) * 2013-04-16 2018-06-20 エシコン・エンド−サージェリィ・インコーポレイテッドEthicon Endo−Surgery,Inc. Drive system separation device for surgical instruments
CN106148216A (en) * 2015-03-27 2016-11-23 浙江海正药业股份有限公司 A kind of streptomycete and the method producing mibemycin A3 thereof

Also Published As

Publication number Publication date
CN109207536A (en) 2019-01-15

Similar Documents

Publication Publication Date Title
US8728796B2 (en) Tiacumicin production
JPH06510913A (en) Production and use of 4,5-dihydrogeldanamycin and its hydroquinone
CN101245362B (en) Method for producing polypeptide antibiotic enramycin by fermentation method
Zhang et al. Development of a defined medium fermentation process for physostigmine production by Streptomyces griseofuscus
CN101967182A (en) Antimicrobial compound and preparation method and application thereof
CN109207536B (en) Method for increasing content of milbemycin A3 in milbemycin fermentation product
WO2010058427A2 (en) Process for production and purification of polymyxin b sulfate
CN113293110B (en) Preparation method of antibacterial lipopeptid compound
CN104651427B (en) A method of preparing doractin
WO2017049751A1 (en) Dectomax fermentation production method on basis of using oxygen uptake rate (our) as control parameter
CN104388501B (en) A kind of erythromycin preparation method using biology enzyme
CN109517865A (en) A method of utilizing Airlift circulating reactor fermenting and producing avermectin
JP2801966B2 (en) Continuous production method of natamycin
CN1928075B (en) Strain capable of generating avermectin B component and utilization thereof
CN108277243B (en) Preparation method of pseudomonic acid A
CN111434775A (en) Method for preparing daptomycin by fermentation
CN113396214B (en) Method for producing nigericin from streptomyces sp.mcc 0151
CN106520871B (en) Method for producing A40926 by fermentation method
CN108396045A (en) A kind of high yield fermentation method for producing of doractin
CN107338210B (en) Abamectin streptomycete synthetic medium and preparation method of fermentation liquor thereof
CN110468051A (en) A kind of K252A fermentation medium and preparation method thereof
CN104450823B (en) A kind of method for improving nimoctin fermentation yield
CN1364414A (en) Changchuan mycin agricultural bactericide and its preparing method and use
CN112795487B (en) Fermentation medium and fermentation method for producing fusidic acid
CN102604843A (en) Preparation method of fungus fermentation product and application thereof in prevention and treatment of rice diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230616

Address after: 3007, Hengqin international financial center building, No. 58, Huajin street, Hengqin new area, Zhuhai, Guangdong 519031

Patentee after: New founder holdings development Co.,Ltd.

Patentee after: CHONGQING DAXIN PHARMACEUTICAL Co.,Ltd.

Patentee after: Peking University Medical Management Co.,Ltd.

Address before: 100871 8th floor, founder building, 298 Chengfu Road, Haidian District, Beijing

Patentee before: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd.

Patentee before: CHONGQING DAXIN PHARMACEUTICAL Co.,Ltd.

Patentee before: PKU HEALTHCARE INDUSTRY Group